-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, domestic pharmaceutical companies' oncology drug innovation and R&D capabilities have been accumulating, and they are in a period of rapid rise
.
It is understood that there has been continuous good news in the field of anti-tumor drugs in the near future
.
Recently, Shandong New Times Pharmaceutical submitted an application for the 4 types of generic listing of azacitidine for injection and was contracted.
This is the company's sixth product this year
.
Data show that azacitidine for injection is a nucleoside metabolism inhibitor, which can be used to treat moderate-risk-2/high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia with 20-30% bone marrow blasts (AML) and Chronic Myelomonocytic Leukemia (CMML)
.
The original research drug was developed by New Foundation of the United States and was approved for listing in China in 2017.
In 2018, it entered the National Medical Insurance Catalogue through negotiations.
It is now a Category B product of the 2021 National Medical Insurance Catalogue
.
Azacytidine for injection is a "billion-level" anti-tumor injection.
After being included in the national collection, the sales of domestic brands have skyrocketed
.
According to data, Chia Tai Tianqing has become the main player in the azacitidine injection market in the first half of 2021, with a market share of more than 40%.
Another domestic brand, Sichuan Huiyu Pharmaceutical, has also risen to 24.
81%
.
It is worth mentioning that as domestic brands have skyrocketed year after year after they went public, more and more companies are also attracting azacitidine for injection
.
In addition to Shandong New Times Pharmaceuticals, Shanghai Huilun Jiangsu Pharmaceuticals (marketing license holder) and Hausen have received new approvals since 2021, and the acceptance numbers of Jianjin Pharmaceuticals and Yangzijiang are under review and approval
.
The industry believes that from the current number of approved domestic companies and the market space has not yet been fully released, in the future, Shandong New Era Pharmaceutical is expected to gain a share of the market by virtue of its own strength
.
In fact, with the encouragement of national policies and the active contributions of major pharmaceutical companies, the field of anti-tumor drugs continues to send positive news in our country
.
It is understood that, in addition to Shandong New Times Pharmaceuticals recently submitted and accepted application for the 4 types of generic marketing of azacitidine for injection, many innovative anti-tumor drugs have also been approved for clinical use.
.
For example, on November 8, Hengrui Medicine issued an announcement stating that two anti-tumor drugs with a research and development investment of over 640 million yuan were approved for clinical trials
.
The two drugs are Apatinib mesylate tablets and SHR-1701 injection
.
Prior to this, Lianhuan Pharmaceutical also issued an announcement stating that the company had recently received the "Drug Clinical Trial Approval Notice" for LH-1802 capsules (specification: 0.
1mg0.
5mg2mg) approved and issued by the National Medical Products Administration, and Clinical trials will be carried out in the near future
.
It is reported that LH-1802 is a class I anti-tumor innovative drug, and the proposed indication is hematoma or solid
.
On the whole, in 2021, under the background of the accelerated review of new drugs, the research and development of new anti-tumor drugs in China is becoming more and more hot
.
Statistics show that since the beginning of this year, more than 700 new drugs have been approved for clinical use in China, of which anti-tumor drugs account for more than half
.
Since November alone, there have been more than 100 clinically approved new drugs in China, of which nearly seven have become anti-tumor drugs, involving pharmaceutical companies such as Hengrui and Junshi
.
In this context, the industry expects that domestic anti-tumor drugs will usher in a big outbreak, and the competition among enterprises will become increasingly fierce in the future
.
.
It is understood that there has been continuous good news in the field of anti-tumor drugs in the near future
.
Recently, Shandong New Times Pharmaceutical submitted an application for the 4 types of generic listing of azacitidine for injection and was contracted.
This is the company's sixth product this year
.
Data show that azacitidine for injection is a nucleoside metabolism inhibitor, which can be used to treat moderate-risk-2/high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia with 20-30% bone marrow blasts (AML) and Chronic Myelomonocytic Leukemia (CMML)
.
The original research drug was developed by New Foundation of the United States and was approved for listing in China in 2017.
In 2018, it entered the National Medical Insurance Catalogue through negotiations.
It is now a Category B product of the 2021 National Medical Insurance Catalogue
.
Azacytidine for injection is a "billion-level" anti-tumor injection.
After being included in the national collection, the sales of domestic brands have skyrocketed
.
According to data, Chia Tai Tianqing has become the main player in the azacitidine injection market in the first half of 2021, with a market share of more than 40%.
Another domestic brand, Sichuan Huiyu Pharmaceutical, has also risen to 24.
81%
.
It is worth mentioning that as domestic brands have skyrocketed year after year after they went public, more and more companies are also attracting azacitidine for injection
.
In addition to Shandong New Times Pharmaceuticals, Shanghai Huilun Jiangsu Pharmaceuticals (marketing license holder) and Hausen have received new approvals since 2021, and the acceptance numbers of Jianjin Pharmaceuticals and Yangzijiang are under review and approval
.
The industry believes that from the current number of approved domestic companies and the market space has not yet been fully released, in the future, Shandong New Era Pharmaceutical is expected to gain a share of the market by virtue of its own strength
.
In fact, with the encouragement of national policies and the active contributions of major pharmaceutical companies, the field of anti-tumor drugs continues to send positive news in our country
.
It is understood that, in addition to Shandong New Times Pharmaceuticals recently submitted and accepted application for the 4 types of generic marketing of azacitidine for injection, many innovative anti-tumor drugs have also been approved for clinical use.
.
For example, on November 8, Hengrui Medicine issued an announcement stating that two anti-tumor drugs with a research and development investment of over 640 million yuan were approved for clinical trials
.
The two drugs are Apatinib mesylate tablets and SHR-1701 injection
.
Prior to this, Lianhuan Pharmaceutical also issued an announcement stating that the company had recently received the "Drug Clinical Trial Approval Notice" for LH-1802 capsules (specification: 0.
1mg0.
5mg2mg) approved and issued by the National Medical Products Administration, and Clinical trials will be carried out in the near future
.
It is reported that LH-1802 is a class I anti-tumor innovative drug, and the proposed indication is hematoma or solid
.
On the whole, in 2021, under the background of the accelerated review of new drugs, the research and development of new anti-tumor drugs in China is becoming more and more hot
.
Statistics show that since the beginning of this year, more than 700 new drugs have been approved for clinical use in China, of which anti-tumor drugs account for more than half
.
Since November alone, there have been more than 100 clinically approved new drugs in China, of which nearly seven have become anti-tumor drugs, involving pharmaceutical companies such as Hengrui and Junshi
.
In this context, the industry expects that domestic anti-tumor drugs will usher in a big outbreak, and the competition among enterprises will become increasingly fierce in the future
.
